Education
About Us
Working with TipRanks
Follow Us
Clinigence Holdings (NUTX)
NASDAQ:NUTX
NUTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.16 - $184.28
Previous CloseN/A
Volume3.28K
Average Volume (3M)152.84K
Market Cap
$650.89M
Enterprise Value$12.28B
Total Cash (Recent Filing)$87.67M
Total Debt (Recent Filing)$312.50M
Price to Earnings (P/E)10.1
Beta2.20
Next Earnings
Aug 07, 2025EPS Estimate
-1.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.56
Shares Outstanding5,555,116
10 Day Avg. Volume160,504
30 Day Avg. Volume152,839
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)125.66
Price to Sales (P/S)0.00
P/FCF Ratio334.85
Enterprise Value/Market Cap18.86
Enterprise Value/Revenue7.34
Enterprise Value/Gross Profit40.33
Enterprise Value/Ebitda32.75
Forecast
1Y Price Target
$262.50Price Target Upside110.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Clinigence Holdings News
PremiumCompany Announcements
Clinigence Holdings Reports Robust Growth in Earnings Call
PremiumCompany Announcements
Nutex Health Reports Strong Q1 2025 Financial Growth
Bulls Say, Bears Say
Bulls Say
EarningsNutex reported a 1Q beat with revenue of $211.9M, up 214% year over year.
Expansion StrategyThe company remains on track with its network expansion strategy, with three new micro-hospitals slated to open in Texas during 2H25 and a broader pipeline of seven De Novo facilities with targeted openings in 2026-2028.
Financial PerformanceNUTX's growing free cash flow from operations, which increased to $51.0M in 1Q25, from $3.1M in 1Q24, may support acceleration of these expansion plans.
Bears Say
Business ModelShares currently trade at a discount to peers, reflecting the early stage and unproven nature of Nutex's business model.
Risk ManagementSuccessful rate arbitration with payors accounted for approximately $105M of revenue, significantly higher than the estimate, indicating potential volatility in revenue streams.
Stock ValuationShares currently trade at a discount to peers, reflecting the early stage and unproven nature of Nutex's business model.
Options Prices
Currently, No data available
---
Ownership Overview
35.60% Insiders
3.74% Mutual Funds
5.69% Other Institutional Investors
51.07% Public Companies and Individual Investors
NUTX FAQ
What was Clinigence Holdings’s price range in the past 12 months?
Clinigence Holdings lowest stock price was $4.16 and its highest was $184.28 in the past 12 months.
What is Clinigence Holdings’s market cap?
Clinigence Holdings’s market cap is $650.89M.
When is Clinigence Holdings’s upcoming earnings report date?
Clinigence Holdings’s upcoming earnings report date is Aug 07, 2025 which is in 54 days.
How were Clinigence Holdings’s earnings last quarter?
Clinigence Holdings released its earnings results on May 13, 2025. The company reported $2.56 earnings per share for the quarter, beating the consensus estimate of N/A by $2.56.
Is Clinigence Holdings overvalued?
According to Wall Street analysts Clinigence Holdings’s price is currently Undervalued.
Does Clinigence Holdings pay dividends?
Clinigence Holdings does not currently pay dividends.
What is Clinigence Holdings’s EPS estimate?
Clinigence Holdings’s EPS estimate is -1.48.
How many shares outstanding does Clinigence Holdings have?
Clinigence Holdings has 5,555,116 shares outstanding.
What happened to Clinigence Holdings’s price movement after its last earnings report?
Clinigence Holdings reported an EPS of $2.56 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 26.102%.
Which hedge fund is a major shareholder of Clinigence Holdings?
Currently, no hedge funds are holding shares in NUTX
Clinigence Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$262.50 (110.12% Upside)
$262.50 (110.12% Upside)
Blogger Sentiment
Neutral
NUTX Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 222.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $81.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 18.6%
Last 30 Days ▲ 214.7%
Last 30 Days ▲ 214.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1984.03%
12-Months-Change
Fundamentals
Return on Equity
51.65%
Trailing 12-Months
Asset Growth
88.46%
Trailing 12-Months
Company Description
Clinigence Holdings
Clinigence Holdings (NUTX) is a healthcare technology company operating in the United States. The company focuses on providing data-driven solutions to improve healthcare delivery and outcomes. Its core products and services include advanced analytics, population health management, and value-based care solutions designed to support healthcare providers and organizations in optimizing their operations and enhancing patient care.
NUTX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in patient visits, revenue, and profitability, alongside effective arbitration processes and expansion plans. However, challenges remain in the arbitration process and non-cash expenses impacting financials. Overall, positive progress was reported despite some ongoing challenges.Read More>NUTX Stock 12 Month Forecast
Average Price Target
$262.50
▲(110.12%Upside)
Technical Analysis
aTyr Pharma
―
Inventiva
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Candel Therapeutics
―